鈥楢n Arm and a Leg鈥: The New Cap on Medicare Drug Costs
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
Drugs
361-380 of 1,313 results
-
-
Readers and Tweeters Place Value on Community Services and Life-Sustaining Care
KHN gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat the Health?鈥: Wrapping Up Summer鈥檚 Health News
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
-
For Medically Vulnerable Families, Inflation鈥檚 Squeeze Is Inescapable
Inflation hasn鈥檛 hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.
-
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn鈥檛 materialized.
By Arthur Allen -
No, the Senate-Passed Reconciliation Bill Won鈥檛 Strip $300 Billion From Medicare
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn鈥檛 result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
-
A GOP Talking Point Suggests Birth Control Is Not at Risk. Evidence Suggests Otherwise.
Republicans say Democrats are wrong to claim that birth control could be the Supreme Court鈥檚 next target. But Democrats have plenty of evidence that it might be.
By Julie Rovner -
Watch: Explaining the Nitty-Gritty of Medicare Drug Price Negotiations 鈥 And Patients’ Potential Savings
KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats鈥 plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.
-
Everything You Need to Know About Paxlovid 鈥 Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
-
Listen: Can California Lower the Price of Insulin?
California Healthline senior correspondent Angela Hart describes California鈥檚 ambitious plan to manufacture generic insulin under the state鈥檚 new 鈥淐alRx鈥 drug label.
-
Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations
The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that鈥檚 not the case and that such policies would instead reduce costs for the Medicare program and seniors.
By Victoria Knight and Colleen DeGuzman -
KHN鈥檚 鈥榃hat the Health?鈥: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
-
Parents Become Drug Developers to Save Their Children鈥檚 Lives
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
-
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when 鈥 not if 鈥攖he old ones fail.
By Arthur Allen -
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat the Health?鈥: Life After 鈥楻oe鈥 Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Patients With Epilepsy Navigate Murky Unregulated CBD Industry
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
By Eric Berger -
Seeking to Kick-Start Biden鈥檚 Agenda, Schumer Unveils a Bill for Medicare Drug Price Negotiations
In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.
-
‘Free’ Screening? Know Your Rights to Get No-Cost Care
Even a decade in, the Affordable Care Act鈥檚 recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.
-
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government鈥檚 covid-fighting strategy.
By Arthur Allen